Brachytherapy boost for prostate cancer: Trends in care and survival outcomes
- 1 February 2017
- journal article
- Published by Elsevier BV in Brachytherapy
- Vol. 16 (2), 330-341
- https://doi.org/10.1016/j.brachy.2016.12.015
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupBJU International, 2012
- Phase II Trial of Combined High-Dose-Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321International Journal of Radiation Oncology*Biology*Physics, 2010
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- Hypofractionated Boost With High-Dose-Rate Brachytherapy and Open Magnetic Resonance Imaging–Guided Implants for Locally Aggressive Prostate Cancer: A Sequential Dose-Escalation Pilot StudyInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialThe Lancet Oncology, 2007
- Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waitingScandinavian Journal of Urology and Nephrology, 2007
- Hypofraktionierte konformale HDR-Brachytherapie bei hormonnaiven Patienten mit lokalisiertem Prostatakarzinom. Ist die Eskalation auf sehr hohe biologisch äquivalente Dosen bei allen prognostischen Risikogruppen von Vorteil?Strahlentherapie und Onkologie, 2006